Orexigen Therapeutics Company Profile (NASDAQ:OREX)

About Orexigen Therapeutics

Orexigen Therapeutics logoOrexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: OREX
  • CUSIP: 68616410
Key Metrics:
  • Previous Close: $4.44
  • 50 Day Moving Average: $3.88
  • 200 Day Moving Average: $3.14
  • 52-Week Range: $14,586,000.00 - $1.65
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.66
  • P/E Growth: 0.01
  • Market Cap: $64.76M
  • Outstanding Shares: 14,586,000
  • Beta: 2.72
Profitability:
  • Net Margins: -71.59%
  • Return on Equity: -354.92%
  • Return on Assets: -29.11%
Debt:
  • Debt-to-Equity Ratio: 2.74%
  • Current Ratio: 4.17%
  • Quick Ratio: 3.81%
Additional Links:
Companies Related to Orexigen Therapeutics:

Analyst Ratings

Consensus Ratings for Orexigen Therapeutics (NASDAQ:OREX) (?)
Ratings Breakdown: 5 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $1.50 (66.22% downside)

Analysts' Ratings History for Orexigen Therapeutics (NASDAQ:OREX)
Show:
DateFirmActionRatingPrice TargetDetails
3/16/2016Leerink SwannLower Price TargetMarket Perform$2.00 -> $1.00View Rating Details
3/16/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$5.00 -> $2.00View Rating Details
3/16/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
2/29/2016J P Morgan Chase & CoDowngradeOverweight -> NeutralView Rating Details
2/29/2016Royal Bank of CanadaDowngradeOutperform -> Sector Perform$5.00 -> $1.00View Rating Details
12/16/2015WallachBeth CapitalDowngradeBuy -> HoldView Rating Details
12/12/2015Bank of America CorpReiterated RatingSellView Rating Details
12/4/2015Wells Fargo & CoDowngradeOutperform -> Market PerformView Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Orexigen Therapeutics (NASDAQ:OREX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2017        
2/27/2017Q4 2016($1.18)N/AView Earnings Details
11/3/2016Q316($2.24)$1.12$8.17 million$7.00 millionViewN/AView Earnings Details
8/4/2016Q216($1.47)($1.73)$6.88 million$7.79 millionViewListenView Earnings Details
5/4/2016Q116($0.17)($0.15)$7.78 million$5.00 millionViewListenView Earnings Details
2/26/2016Q415($0.08)($0.12)$14.07 million$4.90 millionViewListenView Earnings Details
11/5/2015Q315($0.16)($0.09)$12.17 million$10.00 millionViewListenView Earnings Details
8/6/2015Q215($0.17)($0.18)$4.92 million$5.20 millionViewListenView Earnings Details
5/8/2015Q115($0.16)($0.14)$7.28 million$4.36 millionViewListenView Earnings Details
11/10/2014Q3($0.13)$0.09$8.93 million$30.90 millionViewListenView Earnings Details
8/7/2014Q2($0.21)($0.21)$1.00 millionViewListenView Earnings Details
5/8/2014Q1($0.20)($0.23)ViewListenView Earnings Details
3/12/2014Q4($0.19)($0.21)$900.00 million$857.00 millionViewListenView Earnings Details
11/12/2013Q3($0.18)($0.19)$0.80 million$0.86 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.19)($0.19)$0.90 millionViewListenView Earnings Details
3/13/2013Q4 2012($0.44)($0.41)$0.91 million$0.86 millionViewListenView Earnings Details
11/7/2012Q312($0.30)($0.44)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Orexigen Therapeutics (NASDAQ:OREX)
Current Year EPS Consensus Estimate: $-9.70 EPS
Next Year EPS Consensus Estimate: $-6.72 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.09)($0.09)($0.09)
Q2 20162($0.14)($0.10)($0.12)
Q3 20162($0.18)($0.10)($0.14)
Q4 20162($0.15)($0.11)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Orexigen Therapeutics (NASDAQ:OREX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Orexigen Therapeutics (NASDAQ:OREX)
Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 49.65%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/19/2016Stephen A. MogliaVPSell800$1.96$1,568.00View SEC Filing  
12/2/2014Heather D TurnerSVPSell22,643$6.00$135,858.00View SEC Filing  
11/25/2014Heather D TurnerSVPSell31,388$5.83$182,992.04View SEC Filing  
11/18/2014Louis C BockDirectorBuy1,325$5.58$7,393.50View SEC Filing  
11/12/2014Louis C BockDirectorBuy27,052$5.57$150,679.64View SEC Filing  
9/22/2014Heather D TurnerVPSell300,000$4.47$1,341,000.00View SEC Filing  
9/15/2014Joseph P HaganVPBuy5,000$4.69$23,450.00View SEC Filing  
9/15/2014Michael NarachiCEOBuy50,000$4.78$239,000.00View SEC Filing  
7/31/2013Joseph P HaganInsiderSell12,000$7.80$93,600.00View SEC Filing  
7/26/2013Joseph P HaganInsiderSell10,000$7.40$74,000.00View SEC Filing  
7/25/2013Preston KlassenSVPSell71,229$7.16$509,999.64View SEC Filing  
5/28/2013Joseph P HaganInsiderSell28,000$7.00$196,000.00View SEC Filing  
5/28/2013Preston KlassenSVPSell28,771$7.21$207,438.91View SEC Filing  
1/15/2013Mark D BoothInsiderSell22,315$6.67$148,841.05View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Orexigen Therapeutics (NASDAQ:OREX)
DateHeadline
biz.yahoo.com logoOREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fina (NASDAQ:OREX)
biz.yahoo.com - February 24 at 8:08 PM
News IconInside Track: Trading Focus on Shares of Orexigen Therapeutics Inc (OREX) - Rives Journal (NASDAQ:OREX)
rivesjournal.com - February 22 at 7:10 PM
News IconAre Analysts Optimistic About Where Orexigen Therapeutics, Inc. (NASDAQ:OREX) is Heading? - Winfield Review (NASDAQ:OREX)
winfieldreview.com - February 22 at 7:10 PM
seekingalpha.com logoOrexigen: Smart Convert Exchange Is Bullish For Equity - Seeking Alpha (NASDAQ:OREX)
seekingalpha.com - February 22 at 7:10 PM
News IconManaging Obesity in Primary Care: When It's Time for Gastric Bypass Surgery (NASDAQ:OREX)
www.medscape.com - February 21 at 5:49 PM
marketexclusive.com logoOREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:OREX)
marketexclusive.com - February 20 at 9:37 AM
reuters.com logoBRIEF-Orexigen Therapeutics sees Q4 total revenue $13.4-$13.9 mln (NASDAQ:OREX)
uk.reuters.com - February 17 at 4:44 PM
biz.yahoo.com logoOREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and (NASDAQ:OREX)
biz.yahoo.com - February 17 at 4:44 PM
News IconOrexigen Therapeutics, Inc. (NASDAQ:OREX) Bearish Target At $5 - Stock Observer (NASDAQ:OREX)
www.thestockobserver.com - February 17 at 8:12 AM
News IconMarket Update on Shares of Orexigen Therapeutics Inc. (OREX) - BVN (NASDAQ:OREX)
bvnewsjournal.com - February 17 at 8:12 AM
News IconForward Earnings Estimate of Orexigen Therapeutics, Inc.(OREX ... - Highland Mirror (NASDAQ:OREX)
www.highlandmirror.com - February 11 at 1:01 AM
marketexclusive.com logoOREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX) Files An 8-K Regulation FD Disclosure (NASDAQ:OREX)
marketexclusive.com - February 9 at 8:09 PM
finance.yahoo.com logoOrexigen Therapeutics to Speak at Upcoming Investor Conferences (NASDAQ:OREX)
finance.yahoo.com - February 7 at 8:09 PM
News IconObesity: When Diet Is a Treatment, Not Just a Diet (NASDAQ:OREX)
www.medscape.com - February 6 at 7:07 PM
realistinvestor.com logoOrexigen Therapeutics, Inc. (NASDAQ:OREX) EPS Projection At $-0.43 - RealistInvestor.com (NASDAQ:OREX)
www.realistinvestor.com - February 4 at 5:54 AM
News IconMaking Cardiology Family-Friendly Helps Men and Women (NASDAQ:OREX)
www.medscape.com - February 2 at 8:00 PM
4-traders.com logoOrexigen Therapeutics : Drug Makers Stocks on Investors' Radar -- Depomed, United Therapeutics, DURECT, and Orexigen Therapeutics (NASDAQ:OREX)
www.4-traders.com - January 31 at 8:00 AM
prnewswire.com logoDrug Makers Stocks on Investors' Radar -- Depomed, United Therapeutics, DURECT, and Orexigen Therapeutics (NASDAQ:OREX)
www.prnewswire.com - January 31 at 8:00 AM
News IconConsensus Estimates on Earnings & Stock Price in Focus for Orexigen Therapeutics, Inc. (NASDAQ:OREX) Shares - Aiken Advocate (NASDAQ:OREX)
aikenadvocate.com - January 30 at 7:43 PM
investornewswire.com logoOrexigen Therapeutics, Inc. (NASDAQ:OREX) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:OREX)
www.investornewswire.com - January 30 at 7:43 PM
News IconOrexigen Therapeutics, Inc. (NASDAQ:OREX) Daily Sentiment Score At 0.041 - Stock Observer (NASDAQ:OREX)
www.thestockobserver.com - January 30 at 7:43 PM
News IconOrexigen Therapeutics Inc OREX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:OREX)
www.bioportfolio.com - January 30 at 8:42 AM
News IconStock Checkup: Technical Watch on Orexigen Therapeutics Inc. (OREX) - Rives Journal (NASDAQ:OREX)
rivesjournal.com - January 28 at 7:10 PM
News IconEarnings in Full Force, Analysts Take Aim at Orexigen Therapeutics, Inc. (NASDAQ:OREX) - Wall Street Beacon (NASDAQ:OREX)
wsbeacon.com - January 26 at 4:21 AM
News IconEnlivened Volatility Spotted in Shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) - Wall Street Beacon (NASDAQ:OREX)
wsbeacon.com - January 26 at 4:21 AM
prnewswire.com logoOrexigen Therapeutics Announces Spanish Launch of Mysimba® (naltrexone HCl / bupropion HCl prolonged release ... - PR Newswire (press release) (NASDAQ:OREX)
www.prnewswire.com - January 26 at 4:20 AM
4-traders.com logoOrexigen Therapeutics : OREX) Gains on Product Launch (NASDAQ:OREX)
www.4-traders.com - January 25 at 11:19 PM
reuters.com logoBRIEF-Orexigen Therapeutics announces spanish launch of Mysimba (NASDAQ:OREX)
www.reuters.com - January 25 at 11:19 PM
finance.yahoo.com logoOrexigen Therapeutics Announces Spanish Launch of Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Partnership with Laboratorios Farmacéuticos Rovi, S.A. (NASDAQ:OREX)
finance.yahoo.com - January 25 at 11:19 PM
News IconWall Street Holds Inauguration Gains, How Did This Stock Fare: Orexigen Therapeutics, Inc. (NASDAQ:OREX) - Wall Street Beacon (NASDAQ:OREX)
wsbeacon.com - January 23 at 9:38 AM
News IconTrading Insight: Taking a Look at Levels for Orexigen Therapeutics Inc. (OREX) - Rives Journal (NASDAQ:OREX)
rivesjournal.com - January 21 at 7:50 AM
realistinvestor.com logoOrexigen Therapeutics, Inc. (NASDAQ:OREX) EPS Estimate At $-0.43 - RealistInvestor.com (NASDAQ:OREX)
www.realistinvestor.com - January 21 at 7:50 AM
News IconAmplified Volatility Spotted in Shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) - Wall Street Beacon (NASDAQ:OREX)
wsbeacon.com - January 21 at 7:50 AM
News IconObesity Is a Disease That Needs to Be Taken Seriously (NASDAQ:OREX)
www.medscape.com - January 19 at 11:42 PM
News IconInvestors Priming the Pump as Stock Reaches Most Volatile List: Orexigen Therapeutics, Inc. (NASDAQ:OREX) - Wall Street Beacon (NASDAQ:OREX)
wsbeacon.com - January 18 at 12:27 AM
News IconStock Momentum Skidding to a Halt For Orexigen Therapeutics, Inc. (NASDAQ:OREX) - Wall Street Beacon (NASDAQ:OREX)
wsbeacon.com - January 18 at 12:27 AM
seekingalpha.com logoOrexigen (OREX) Presents At 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:OREX)
seekingalpha.com - January 12 at 7:42 PM
News IconOrexigen Therapeutics, Inc. (NASDAQ:OREX) Insider Ownership ... - The Newburgh Press (NASDAQ:OREX)
newburghpress.com - January 10 at 7:57 PM
finance.yahoo.com logoOrexigen Therapeutics (OREX) Shares March Higher, Can It Continue? (NASDAQ:OREX)
finance.yahoo.com - January 10 at 7:57 PM
News IconOrexigen Therapeutics, Inc. (NASDAQ:OREX) Daily Sentiment Score At -0.068 - Stock Observer (NASDAQ:OREX)
www.thestockobserver.com - January 10 at 12:45 AM
marketexclusive.com logoOREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX) Files An 8-K Regulation FD Disclosure - Market Exclusive (NASDAQ:OREX)
marketexclusive.com - January 10 at 12:45 AM
biz.yahoo.com logoOREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:OREX)
us.rd.yahoo.com - January 9 at 7:44 PM
News IconThousands of youngsters across Hampshire facing battle against obesity (NASDAQ:OREX)
www.newsoneplace.com - January 9 at 4:49 AM
News IconEe aw-lways does that! Donkey shows off his brains by using his TEETH to remove a fence getting in his way (NASDAQ:OREX)
www.newsoneplace.com - January 8 at 6:46 PM
News IconOrexigen Therapeutics Announces Publication of Contrave® (naltrexone HCl and bupropion HCl ... (NASDAQ:OREX)
www.biomedreports.com - January 6 at 7:46 PM
finance.yahoo.com logoOrexigen Therapeutics Announces Publication of Contrave® (naltrexone HCl and bupropion HCl extended-release … (NASDAQ:OREX)
finance.yahoo.com - January 6 at 7:46 PM
publicnow.com logoOrexigen Therapeutics Announces Publication of Contrave® (naltrexone HCl and bupropion HCl extended-release tablets) Real-World Study Results in "Obesity" (NASDAQ:OREX)
www.publicnow.com - January 6 at 7:46 PM
News IconIn The Midst Of A Business Transformation? GameStop CFO On How To Be A Key Player (NASDAQ:OREX)
www.newsoneplace.com - January 6 at 4:49 AM
reuters.com logoBRIEF-Orexigen therapeutics anticipates filing of new drug submission for Contrave (NASDAQ:OREX)
www.reuters.com - January 6 at 4:49 AM
prnewswire.com logoOrexigen Therapeutics Highlights Key Business Priorities for 2017 - PR Newswire (press release) (NASDAQ:OREX)
www.prnewswire.com - January 5 at 11:48 PM

Social

What is Orexigen Therapeutics' stock symbol?

Orexigen Therapeutics trades on the NASDAQ under the ticker symbol "OREX."

Where is Orexigen Therapeutics' stock going? Where will Orexigen Therapeutics' stock price be in 2017?

5 analysts have issued 1-year target prices for Orexigen Therapeutics' stock. Their predictions range from $1.00 to $2.00. On average, they anticipate Orexigen Therapeutics' share price to reach $1.50 in the next twelve months.

When will Orexigen Therapeutics announce their earnings?

Orexigen Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

Who owns Orexigen Therapeutics stock?

Orexigen Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Baupost Group LLC MA (15.27%), Foresite Capital Management II LLC (3.72%), Foresite Capital Management III LLC (1.74%) and Old West Investment Management LLC (1.41%).

Who bought Orexigen Therapeutics stock? Who is buying Orexigen Therapeutics stock?

Orexigen Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Old West Investment Management LLC.

How do I buy Orexigen Therapeutics stock?

Shares of Orexigen Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Orexigen Therapeutics stock cost?

One share of Orexigen Therapeutics stock can currently be purchased for approximately $4.44.

Orexigen Therapeutics (NASDAQ:OREX) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Orexigen Therapeutics (NASDAQ:OREX)

Earnings History Chart

Earnings by Quarter for Orexigen Therapeutics (NASDAQ:OREX)

Dividend History Chart

Dividend Payments by Quarter for Orexigen Therapeutics (NASDAQ:OREX)

Last Updated on 2/27/2017 by MarketBeat.com Staff